Thromb Haemost 2014; 112(06): 1312-1318
DOI: 10.1160/th14-02-0176
New Technologies, Diagnostic Tools and Drugs
Schattauer GmbH

Differential impact of unrecognised brain infarction on stroke outcome in non-valvular atrial fibrillation

Tae-Jin Song
1   Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
2   Department of Neurology, Ewha Womans University School of Medicine, Seoul, Korea
,
Jinkwon Kim
3   Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
,
Hye Sun Lee
4   Departments of Biostatistics, Yonsei University College of Medicine, Seoul, Korea
,
Chung Mo Nam
4   Departments of Biostatistics, Yonsei University College of Medicine, Seoul, Korea
,
Hyo Seok Nam
1   Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
,
Eun Hye Kim
1   Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
,
Ki Jeong Lee
1   Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
,
Dongbeom Song
1   Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
,
Ji Hoe Heo
1   Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
,
Young Dae Kim
1   Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
› Author Affiliations
Financial support: This work was supported by a grant of the Korea Healthcare Technology R&D Project through the Korean Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI10C2020).
Further Information

Publication History

Received: 26 February 2014

Accepted after major revision: 30 July 2014

Publication Date:
18 November 2017 (online)

Summary

There has been little information regarding the impact of unrecognised brain infarctions (UBIs) on stroke outcome in patients with nonvalvular atrial fibrillation (NVAF). By using volumetric analysis of ischaemic lesions, we evaluated the potential impact of UBIs on clinical outcome according to their presence and categorised type. This study enrolled 631 patients with NVAF having no clinical stroke history. UBIs were categorised into three types as territorial, lacunar, or subcortical. We collected stroke severity, functional outcome at three months, and the total volume of UBIs and acute infarction lesions. We investigated the association between clinical outcome and the type or volume of UBI, using a linear mixed model and logistic regression analysis. UBIs were detected in 285 (45.2 %) patients; territorial UBIs were observed in 24.4 % of patients (154/631), lacunar UBIs in 25 % (158/631), and subcortical UBIs in 15.7 % (99/631). Although initial stroke severity was not different between patients with UBIs and those without, those with UBIs had less improvement during hospitalisation, leading to poorer outcome at three months. Among the three types of UBIs, only territorial UBIs were associated with poor outcome, especially in patients with relatively smaller acute infarction volume. UBIs, in particular, territorial UBIs, may be considered as predictors for poor outcome after ischaemic stroke in patients with NVAF. Our results suggest that the impact of UBIs on clinical outcome differs according to the type of UBIs and the acute stroke severity.

 
  • References

  • 1 Kobayashi A, Iguchi M, Shimizu S. et al. Silent cerebral infarcts and cerebral white matter lesions in patients with nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis 2012; 21: 310-317.
  • 2 Hara M, Ooie T, Yufu K. et al. Silent cortical strokes associated with atrial fibrillation. Clin Cardiol 1995; 18: 573-574.
  • 3 Vermeer SE, Longstreth Jr., WT, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol 2007; 06: 611-619.
  • 4 Cho AH, Kwon SU, Kim TW. et al. High prevalence of unrecognized cerebral infarcts in first-ever stroke patients with cardioembolic sources. Eur J Neurol 2009; 16: 838-842.
  • 5 Jurgensen HS, Nakayama H, Raaschou HO. et al. Silent infarction in acute stroke patients. Prevalence, localization, risk factors, and clinical significance: the Copenhagen Stroke Study. Stroke 1994; 25: 97-104.
  • 6 Vermeer SE, Hollander M, van Dijk EJ. et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126-1129.
  • 7 Putaala J, Haapaniemi E, Kurkinen M. et al. Silent brain infarcts, leukoaraiosis, and long-term prognosis in young ischemic stroke patients. Neurology 2011; 76: 1742-1749.
  • 8 Bokura H, Kobayashi S, Yamaguchi S. et al. Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study. J Stroke Cerebrovasc Dis 2006; 15: 57-63.
  • 9 Kim YS, Park SS, Lee SH. et al. Reduced severity of strokes in patients with silent brain infarctions. Eur J Neurol 2011; 18: 962-971.
  • 10 Corea F, Henon H, Pasquier F. et al. Silent infarcts in stroke patients: patient characteristics and effect on 2-year outcome. J Neurol 2001; 248: 271-278.
  • 11 Lee BI, Nam HS, Heo JH. et al. Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis 2001; 12: 145-151.
  • 12 Choi HY, Seo JH, Yang JH. et al. Beneficial effects of stroke-unit care in stroke patients with atrial fibrillation. Yonsei Med J 2013; 54: 301-305.
  • 13 Song TJ, Kim J, Lee HS. et al. The frequency of cerebral microbleeds increases with CHADS(2) scores in stroke patients with non-valvular atrial fibrillation. Eur J Neurol 2013; 20: 502-508.
  • 14 Vermeer SE, Koudstaal PJ, Oudkerk M. et al. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002; 33: 21-25.
  • 15 Wardlaw JM, Smith EE, Biessels GJ. et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822-838.
  • 16 Song TJ, Kim J, Yang SH. et al. Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients. Biomarkers 2012; 17: 738-744.
  • 17 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
  • 18 Adams Jr., HP, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
  • 19 Das R, Seshadri S, Beiser AS. et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke 2008; 39: 2929-2935.
  • 20 Falsetti P, Acciai C, Palilla R. et al. Oropharyngeal dysphagia after stroke: incidence, diagnosis, and clinical predictors in patients admitted to a neurorehabilitation unit. J Stroke Cerebrovasc Dis 2009; 18: 329-335.
  • 21 Nakagawa T, Sekizawa K, Nakajoh K. et al. Silent cerebral infarction: a potential risk for pneumonia in the elderly. J Intern Med 2000; 247: 255-259.
  • 22 Wang YD, Li XP, Li M. et al. Relationship between cerebral hypoxic tissue volume and prognosis after stroke. Eur Neurol 2010; 63: 52-59.
  • 23 European Heart Rhythm A European, Association for Cardio-Thoracic S, Camm AJ. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
  • 24 Furie KL, Goldstein LB, Albers GW. et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012; 43: 3442-3453.
  • 25 Skanes AC, Healey JS, Cairns JA. et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012; 28: 125-136.